United Therapeutics (UTHR) CEO exercises options, sells 9,500 shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
United Therapeutics Corp Chairperson and CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. On March 12, 2026, she exercised 9,500 stock options at an exercise price of $146.03 per share, receiving 9,500 shares of common stock.
That same day and on March 16, 2026, she completed open-market sales totaling 9,500 common shares at weighted average prices generally between $531.94 and $544.80. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.
Following these trades, Rothblatt holds 8,414 shares of common stock directly. She also has indirect interests, including 166 shares held by her spouse and shares held in various family trusts, such as 324,518 shares in one trust where family members are beneficiaries.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 9,500 shares ($5,109,148)
Net Sell
19 txns
Insider
ROTHBLATT MARTINE A
Role
Chairperson & CEO
Sold
9,500 shs ($5.11M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 516 | $534.9867 | $276K |
| Exercise | Stock Option | 9,500 | $0.00 | -- |
| Exercise | Common Stock | 9,500 | $146.03 | $1.39M |
| Sale | Common Stock | 640 | $532.16 | $341K |
| Sale | Common Stock | 60 | $532.9733 | $32K |
| Sale | Common Stock | 1,955 | $536.0203 | $1.05M |
| Sale | Common Stock | 1,772 | $536.8318 | $951K |
| Sale | Common Stock | 1,077 | $537.8969 | $579K |
| Sale | Common Stock | 720 | $538.9423 | $388K |
| Sale | Common Stock | 1,240 | $539.8153 | $669K |
| Sale | Common Stock | 400 | $541.3099 | $217K |
| Sale | Common Stock | 600 | $542.3346 | $325K |
| Sale | Common Stock | 356 | $543.2238 | $193K |
| Sale | Common Stock | 164 | $544.5849 | $89K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 8,414 shares (Direct);
Stock Option — 154,500 shares (Direct);
Common Stock — 166 shares (Indirect, by Spouse)
Footnotes (1)
- This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. This transaction was executed in multiple trades at prices ranging from $531.94 to $532.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected This transaction was executed in multiple trades at prices ranging from $532.94 to $532.99. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected This transaction was executed in multiple trades at prices ranging from $534.42 to $535.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected This transaction was executed in multiple trades at prices ranging from $535.45 to $536.44. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected This transaction was executed in multiple trades at prices ranging from $536.45 to $537.44. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected This transaction was executed in multiple trades at prices ranging from $537.47 to $538.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected This transaction was executed in multiple trades at prices ranging from $538.48 to $539.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected This transaction was executed in multiple trades at prices ranging from $539.48 to $540.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected This transaction was executed in multiple trades at prices ranging from $540.73 to $541.69. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected This transaction was executed in multiple trades at prices ranging from $541.86 to $542.85. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected This transaction was executed in multiple trades at prices ranging from $542.88 to $543.86. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected This transaction was executed in multiple trades at prices ranging from $543.90 to $544.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
FAQ
What insider transactions did UTHR CEO Martine Rothblatt report in this Form 4?
Martine Rothblatt reported exercising 9,500 stock options and selling 9,500 United Therapeutics common shares. The trades were structured as an exercise-and-sell sequence, converting options into stock and then disposing of those shares in a series of open-market sales.
Was the UTHR CEO’s stock sale done under a Rule 10b5-1 trading plan?
Yes. The option exercise and resulting stock sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The plan is scheduled to continue until certain option exercises are completed or until December 31, 2026.